Every medicine you have ever taken travelled a long road before it reached you. Scientists discovered it, trials tested it, and regulators approved it. But there is another part of the story that almost nobody talks about. Somebody had to build the factory, prove the equipment worked, and show the regulators that every batch would be safe. That quiet, exacting work has a name. It is called commissioning, qualification and validation, or CQV. And one of the firms that has done it for nearly three decades is PharmEng Technology.
This guide explains what PharmEng Technology is and what CQV actually means. It also shows how the firm’s work fits into the pharmaceutical technology trends reshaping the industry in 2026. Artificial intelligence is redesigning drug discovery, factories are becoming smart, and medicine is becoming personal. None of it works without the engineering discipline that sits underneath. Here is the full picture.
What Is PharmEng Technology?
PharmEng Technology is a global consulting and engineering firm that serves the pharmaceutical, biotechnology and medical device industries. It was founded in 1997 and is headquartered in Toronto, Ontario, Canada. Today it operates as part of Efor Group, a European compliance engineering group. Its services are now presented under the Efor name on its website, pharmeng.com.
The firm does not make drugs. It helps the companies that make drugs build, prove and run their facilities, equipment and computer systems. Its consultants work on the side of the industry that regulators care about most: proof. Proof that a cleanroom stays clean and a steriliser reaches the right temperature every time. The same proof covers the software running a production line, which cannot be quietly changed without a record.
According to the company’s own materials, PharmEng employs more than 300 consultants around the world. Its teams work across the Americas, Europe and Asia, with offices in more than a dozen countries. The client list has included some of the world’s largest drug makers. Sanofi Pasteur’s Toronto site, for example, has used PharmEng’s services for more than 25 years. That figure comes from the firm’s own case material.
| Fact | Detail |
|---|---|
| Founded | 1997 |
| Headquarters | Toronto, Ontario, Canada |
| Parent group | Efor Group |
| Industries served | Pharmaceuticals, biotechnology, medical devices |
| Core services | Commissioning, qualification and validation (CQV), quality systems, regulatory affairs, engineering, training |
| Global reach | More than 300 consultants; projects across the Americas, Europe and Asia |
| Website | pharmeng.com |
One detail worth getting right: the company’s name is spelled PharmEng, with a capital E. Many articles, including older ones, write it as “Pharmeng”. The capital E is part of the brand, and it stands for engineering.
What Does Commissioning, Qualification and Validation Actually Mean?
CQV sounds like jargon, and in a way it is. But the idea behind it is simple. A drug factory cannot sell a single tablet until someone proves that everything in it works exactly as intended. That proof must cover every run, and it must be written down. CQV is the structured process of doing that. It has three parts, and each one answers a different question.
Commissioning asks whether the facility and equipment were built and installed correctly. Did the builders follow the design? Are the pipes connected to the right places? Does the air handling system deliver the airflow the design promised? Commissioning is the first, practical check that what was built matches what was drawn.
Qualification asks whether the equipment works correctly under real conditions. It is usually broken into four stages. The industry knows them by their initials: IQ, OQ, PQ and, for processes, PPQ. Installation qualification checks that equipment was delivered and installed to specification. Operational qualification tests that it works across its full operating range. Performance qualification proves it performs consistently under real production conditions. Process performance qualification does the same for the whole manufacturing process, batch after batch.
Validation is the widest of the three terms. It covers the documented evidence that a process, method or computer system consistently produces the intended result. That includes cleaning validation, sterilisation validation, analytical method validation and computer system validation. In modern plants, the computer systems matter as much as the steel. A production line is run by PLCs and SCADA systems. Manufacturing execution systems (MES), laboratory information systems (LIMS) and enterprise software (ERP) run alongside them. Each one has to be validated so that data cannot be lost, altered or faked without detection.
| Stage | What it proves |
|---|---|
| Commissioning | The facility and equipment were built and installed as designed |
| Installation Qualification (IQ) | Equipment matches its specification and is installed correctly |
| Operational Qualification (OQ) | Equipment works across its full operating range |
| Performance Qualification (PQ) | Equipment performs consistently under real conditions |
| Process Validation (PPQ) | The whole process reliably produces quality product, batch after batch |
| Computer System Validation | Software and data systems are secure, accurate and traceable |
Its CQV work covers equipment qualification, process validation and technology transfer. It also covers digital validation on paperless platforms such as Kneat and ValGenesis. Automated systems, from PLCs to LIMS, are validated too. The firm also works on pharmaceutical quality systems, regulatory affairs and training. It supports clients through FDA pre-approval inspections and other regulatory audits. When a regulator walks into a plant and asks to see the evidence, this is the evidence they mean.
Why Does CQV Matter More in 2026 Than Ever Before?
Drug manufacturing is getting harder, not easier. The medicines that matter most today are more complex than the tablets of the past. Cell and gene therapies are made from living cells. Biologics are grown in bioreactors, not mixed in vats. Personalised treatments are produced in small batches for small groups of patients. Each of these raises the bar for proof, because the margin for error is smaller and the consequences of a mistake are larger.
Regulators have responded by raising the bar too. The European Union’s revised GMP Annex 1, which governs sterile manufacturing, took effect in 2023 and demands far more rigorous contamination control. Data integrity is now a central focus of inspections on both sides of the Atlantic. Regulators expect electronic records to be complete, attributable and protected against tampering, and they expect companies to prove it.
At the same time, the industry is digitising fast. Paper validation binders are giving way to cloud-based platforms with electronic signatures and live dashboards. That shift brings real benefits: faster execution, better traceability and fewer transcription errors. But it also creates new validation work, because every new digital tool has to be qualified before it can be trusted. This is exactly the ground where a firm like PharmEng operates. Its risk-based approach concentrates effort on the controls that matter most for patient safety, which is also what regulators want to see.
How Is AI Changing Drug Discovery in 2026?
If CQV is the quiet discipline underneath pharma, artificial intelligence is the loud revolution on top of it. In 2026, AI is no longer an experiment in drug discovery. It is standard practice at most large drug makers, and the numbers show why. Developing a new medicine the traditional way commonly takes more than a decade and costs more than two billion dollars, and roughly nine out of ten drugs that enter clinical trials still fail. Anything that shortens that road is worth billions.
AI attacks the problem at the earliest stage. Generative chemistry models propose new molecular structures that no human chemist has drawn before. Protein structure prediction tools, led by DeepMind’s AlphaFold, let researchers see the shape of a target protein before they design a drug to fit it. Agentic AI systems go a step further: they plan multi-step research workflows, run them, read the results and adjust the next experiment, with scientists supervising rather than directing every step.
The biggest companies are building dedicated AI infrastructure instead of renting it. Novo Nordisk has set up an AI drug discovery hub with Amazon Web Services, with its own compute, data pipelines and teams working alongside medicinal chemists. Eli Lilly is building an AI supercomputer with NVIDIA, described as an “AI factory” for drug discovery and manufacturing, and has invested 250 million dollars in an AI research partnership with Purdue University. In March 2026, the AI biologics startup Earendil Labs raised 787 million dollars to build its antibody design platform, one of the largest early-stage raises the sector has seen.
Market forecasts reflect the momentum. Fortune Business Insights projects the AI drug discovery market at roughly five billion dollars in 2026, growing to about 12.56 billion dollars by 2034. Industry leaders surveyed by PharmaVoice expect up to 30 per cent of preclinical work to use some form of AI soon, and predict AI could cut drug development costs by around 16 per cent.
But honesty matters here. No AI-originated drug has yet been approved. Several AI-designed candidates have reached Phase I and early Phase II trials, which is genuine progress, but none has cleared Phase III. Insilico Medicine’s rentosertib, an AI-designed treatment for lung fibrosis, was one of the first AI-designed drugs to reach Phase II trials. The field’s boldest claim, that AI can compress discovery from four to six years into twelve to eighteen months, still rests mainly on preclinical and early clinical evidence. Whether that promise holds will become clear over the next few years.
What Is Precision Medicine and Why Is It Growing?
Precision medicine is the idea that treatment should fit the patient, not the average. Instead of giving the same drug to everyone with the same diagnosis, doctors use genetic and molecular information to choose the treatment most likely to work for one person. It started in cancer and rare diseases, where the genetic drivers are clearest. Between 2019 and 2023, more than 10,000 oncology trials were started worldwide, and nearly 30 per cent of them used precision approaches, according to industry reporting.
In 2026, precision medicine is spreading into cardiovascular, neurological and metabolic disease as genomics gets cheaper and AI gets better at reading it. Multi-omics research, which combines genomics with data about proteins, metabolites and the microbiome, is producing a far richer picture of each patient. Companion diagnostics, tests that identify which patients will respond to a specific drug, are now developed alongside the drug itself rather than as an afterthought.
This shift changes manufacturing too. Precision treatments often come in small batches, sometimes one batch per patient. That makes flexible, tightly controlled production essential, and it makes the validation work behind it more demanding. A factory that makes a million identical tablets can rely on routine. That routine breaks down for personalised cell therapies, where every batch is different. Every batch is different, so the proof has to be built into the process itself.
How Are Smart Factories Changing Drug Manufacturing?
The drug factory of 2026 looks very different from the factory of 2016. Sensors track temperature, humidity, pressure and particle counts in real time. Robotic arms handle vials that human hands once touched. Digital twins, virtual copies of a production line, let engineers test changes in software before they touch the real equipment. Pfizer is among the companies that have used digital twins in production, and predictive maintenance has cut equipment downtime by 25 to 30 per cent in at least one reported case.
Continuous manufacturing is another major shift. Instead of making drugs in separate batches, with testing between each step, continuous lines keep material flowing from raw ingredients to finished tablets, with quality checked as it moves. The US FDA has encouraged this approach for years, because it can improve consistency and reduce waste. But continuous lines are harder to validate than batch processes, because there is no natural pause where a human can check the work. The validation has to be designed into the line from the start.
Automation extends beyond the production floor. In packaging, AI vision systems verify serialisation codes at line speed, which matters in the fight against counterfeit medicines, a trade worth an estimated 200 billion dollars a year globally. Smart packaging can even carry a QR code that links patients to instructions and reminders, improving adherence and giving companies real-world data on how their medicines are used.
What Role Does Automation Play in Clinical Trials and Safety?
AI’s influence does not stop at discovery and manufacturing. Clinical trials, the most expensive part of drug development, are being reshaped too. AI helps trial designers choose the right patients, predict who is likely to drop out, and simulate trial outcomes before a single patient is enrolled. It can scan medical records to find undiagnosed or untreated patients far faster than manual searching, which matters for rare diseases where every eligible patient counts.
Drug safety is changing just as fast. Pharmacovigilance, the science of monitoring medicines after they reach the market, now deals with a flood of safety data from trials, prescriptions, social media and wearable devices. AI systems handle automated case processing, detect safety signals earlier, classify adverse events with natural language processing, and monitor risk in real time. In 2026, AI-powered pharmacovigilance is becoming a standard part of regulatory submissions and post-marketing surveillance, not an optional extra.
Regulators are adapting as well. In January 2025, the US FDA issued draft guidance on AI in drug development. It covers using AI to support regulatory decisions for drugs and biological products. Its expectations cover credibility, transparency and bias assessment. Companies that can show their AI tools are validated and their data is trustworthy will move faster through the system. Those that cannot will wait.
How Do PharmEng and Firms Like It Fit Into This New Landscape?
Here is where the two halves of this story meet. AI can design a molecule in months. A smart factory can make it with minimal human touch. But none of that reaches a patient until someone proves, to a regulator’s satisfaction, that the process is controlled, the data is trustworthy and the product is safe. That proof is the bridge between innovation and the market, and it is what firms like PharmEng build.
The work itself is changing with the technology. Validation is going paperless, with cloud platforms replacing binders and wet signatures. Digital validation tools track every test, signature and deviation in one system, with live dashboards instead of end-of-project reports. Computer system validation now covers AI-enabled tools and the data pipelines that feed them. A model is only as good as its data, so the validation of data integrity, from sensor to submission, has become a core service.
There is also a human side that technology cannot replace. Regulators still inspect facilities in person. They still interview staff. Hard questions about why a decision was made come next. Consultants who have sat through dozens of inspections know what those questions sound like, and they prepare their clients accordingly. That experience is difficult to automate, and it is a large part of what clients pay for.
What Should You Look for in a Pharma Engineering Partner?
Not every engineering firm is the same, and choosing one is a decision that can shape a project for years. A few checks separate the strong partners from the rest.
First, look at the track record. Has the firm worked on facilities like yours, with products like yours, under the regulators you answer to? A firm with decades of experience and long-standing clients, such as PharmEng’s 25-year relationship with Sanofi Pasteur in Toronto, brings lessons that a new entrant cannot offer.
Second, check the breadth of services. A project that starts with design will eventually need commissioning, qualification, validation, quality systems and regulatory support. Choosing a firm that covers the full lifecycle keeps knowledge in one place instead of handing it between vendors.
Third, ask about digital capability. Paper-based validation is disappearing. A partner that works fluently with paperless platforms, data analytics and AI-enabled tools will finish faster and leave you with better records.
Fourth, confirm the regulatory knowledge. The firm should be fluent in cGMP compliance, GAMP 5, EU GMP Annex 1, FDA expectations and ICH guidelines. It should also be able to show how its GMP validation work holds up in real inspections.
Finally, look at the people. The consultants who will sit in your facility matter more than any brochure. Ask who they are, what they have validated before, and whether they will stay with the project to the end.
What Comes Next for Pharmaceutical Technology?
The next few years will test whether AI’s promises survive contact with reality. If the current generation of AI-designed candidates succeeds in Phase II and Phase III trials, the first AI-originated drug approvals could arrive before 2030, and the industry’s economics would shift permanently. Failure would still leave the field with faster tools for target discovery and trial design, though the hype would cool.
Other changes are already locked in. The “lab-in-the-loop” model, where AI designs experiments, robots run them and results feed straight back into the model, is moving from pilot projects into real laboratories. Quantum computing pilots for molecular simulation are under way, though useful results are still years away. Cell and gene therapies will keep pushing manufacturing toward smaller, more flexible, more automated facilities. And regulators will keep demanding better evidence, which means the validation discipline that firms like PharmEng provide will only grow in importance.
The lesson of the last thirty years is that innovation and compliance are not opposites. Usually, the fastest movers are the ones with the strongest proof behind them. PharmEng Technology has spent nearly three decades building that proof for others. In 2026, as AI, precision medicine and smart factories rewrite how drugs are discovered and made, that work matters more than ever.
Frequently Asked Questions
What does PharmEng Technology do?
PharmEng Technology is a consulting and engineering firm founded in 1997 in Toronto, Canada. It helps pharmaceutical, biotechnology and medical device companies with commissioning, qualification and validation (CQV), quality systems, regulatory affairs, engineering and training. Today, it operates as part of Efor Group.
What is CQV in pharmaceuticals?
CQV stands for commissioning, qualification and validation. It is the documented process of proving that a drug manufacturing facility, its equipment and its computer systems were built correctly, work correctly and consistently produce safe, quality medicines. Regulators require this evidence before a facility can supply the market.
Has any AI-designed drug been approved yet?
No. As of 2026, no AI-originated drug has been approved. Several AI-designed candidates have reached Phase I and early Phase II trials, including Insilico Medicine’s rentosertib for lung fibrosis. The first approvals, if trial results hold, could come before 2030.
How big is the AI drug discovery market in 2026?
Fortune Business Insights projects the AI drug discovery market at roughly five billion dollars in 2026, growing to about 12.56 billion dollars by 2034. Industry leaders expect up to 30 per cent of preclinical work to use AI in the near future.
What is precision medicine?
Precision medicine tailors treatment to the individual patient using genetic and molecular information, rather than giving the same drug to everyone with the same diagnosis. It began in cancer and rare diseases and is now spreading into heart, brain and metabolic conditions.
Why do drug factories need validation?
Validation proves that a manufacturing process consistently produces medicines of the right quality, batch after batch. Without it, regulators will not allow a facility to supply patients, because there is no evidence that the product is safe. Validation also protects patients when something goes wrong, because the records show exactly what happened.
Sources: PharmEng Technology / Efor Group (pharmeng.com); ISPE sponsor profile; BIO International Convention exhibitor directory; AIDrugSearch 2026 AI drug discovery trends; PharmaVoice 2026 predictions; IntuitionLabs AI biologics and pharma AI vendor reports 2026; Express Pharma 2026 pharma trends; Pharmaceutical Technology (PharmTech) 2026 industry interviews.















